Thursday, January 24, 2019 12:02:54 PM
Before the respiratory effect of Ampakines was discovered, the thrust of Cortex's research (prior to the Cortex-Pier merger that created RSPI) was on improving cognition and memory. Ampakines work by upregulating AMPA (a type of glutamate receptor), and the research in the article involves a different mechanism to achieve the similar result of increasing / restoring glutamate receptor activity.
It's good to see that glutamate related research continues. Ampakines could be rediscovered. The ADHD results (CX-717) were particularly strong (2006) and a pharma partnering deal was reportedly imminent, but the histological 'artifact' phenomenon was found with CX-717 which derailed the compound. Since then, research by RSPI has apparently shown conclusively that the histological finding is a non issue, and RSPI have CX-717 back in the pipeline for future clinical development (pending funding).
Another key factor with ADHD back in the 2006 period was the FDA's apparent reversal on approving new cognitive enhancers. After approving Strattera (2002) the FDA seemed to lose all enthusiasm for new cognitive enhancers, and pharma interest into ADHD seemed to dry up. In 2005, Strattera received a 'black box' warning (suicidal thoughts), which likely cooled the FDA's jets on any new ADHD approvals, plus Ritalin and Adderall had long been abused by teenagers.
Strattera's claim to fame was that it was a non-stimulant, in contrast to ADHD drugs like Adderall (Speed/amphetamine). Strattera works at the norepinephrine receptor, but ended up with the black box warning. Ampakines like CX-717 have none of those problems, and in its Phase 2, CX-717 blew away Strattera efficacy-wise -
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=82879930
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM